TherapeuticsMD (TXMD) Tax Provisions (2011 - 2025)

TherapeuticsMD's (TXMD) quarterly Tax Provisions came in at -$32000.0 in Q1 2025, up 89.33% quarter-over-quarter from -$300000.0 in Q3 2022.

Analysis

TherapeuticsMD (TXMD) Tax Provisions (2011 - 2025) Analysis & Trends

TherapeuticsMD (TXMD) has reported Tax Provisions for 3 consecutive years, with -$32000.0 the latest figure, recorded in Q1 2025.

For the quarter ending Q1 2025, Tax Provisions changed N/A year-over-year to -$32000.0; the trailing twelve-month figure through Sep 2025 stood at -$332000.0 (changed N/A YoY), and the FY2024 full-year result was -$31000.0, up 27.91% from the prior year.
Tax Provisions advanced to -$32000.0 in Q1 2025 per TXMD's latest filing, from -$300000.0 in the prior quarter.
Across five years, Tax Provisions topped out at $600000.0 in Q2 2022 and bottomed at -$300000.0 in Q3 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Johnson & Johnson	650.65 Bn	629.89 Bn	17.26 Bn	1.21 Bn
2	AbbVie	466.34 Bn	459.82 Bn	12.70 Bn	662.00 Mn
3	Merck	362.11 Bn	355.02 Bn	12.21 Bn	654.00 Mn
4	Novartis Ag	267.81 Bn	260.52 Bn	11.24 Bn	-1.01 Bn
5	Pfizer	157.31 Bn	145.91 Bn	10.94 Bn	-407.00 Mn
6	Bristol Myers Squibb	128.75 Bn	117.69 Bn	9.25 Bn	770.00 Mn
7	Sanofi	51.80 Bn	44.84 Bn	10.79 Bn	-524.23 Mn
8	Revolution Medicines	40.91 Bn	40.91 Bn	-	-
9	BeOne Medicines	39.65 Bn	34.55 Bn	1.53 Bn	75.45 Mn
10	TherapeuticsMD	25.35 Mn	16.16 Mn	-	-

Historic Data

Download Data